AbbVie has executed a major acquisition by purchasing Capstan Therapeutics for up to $2.1 billion, marking its entrance into the in vivo CAR-T therapy market. Capstan, founded in 2022, focuses on CAR-T treatments targeting autoimmune conditions, fibrosis, and cancer. The deal underscores AbbVie’s strategic commitment to expanding its innovative cell therapy pipeline. Established investors backing Capstan include venture arms of Pfizer and Bristol Myers Squibb, highlighting broad industry confidence in this nascent therapeutic area.